- ￥569 - 1989
- MedChemExpress(MCE)
- 美国
- HY-13235
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
GSK1210151A
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1300031-49-5
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1377.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥569.0 |
| 规格： | 5 mg | 产品价格： | ￥1252.0 |
| 规格： | 10 mg | 产品价格： | ￥1989.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
I-BET151
CAS No. : 1300031-49-5
MCE 国际站：I-BET151
产品活性：I-BET151 (GSK1210151A) 是一种 BET 溴结构域 (BET bromodomain) 抑制剂，抑制 BRD4，BRD2 和 BRD3 的 pIC50 分别为 6.1，6.3 和 6.6。
研究领域：Epigenetics
作用靶点：Epigenetic Reader Domain
In Vitro: I-BET151 (1 μM; 72 hours) treatment displays the majority of live cells resided in the G0 phase and commensurate with a dose- and time-dependent decrease in cell proliferation and abrogation of bromodeoxyuridine incorporation.
?I-BET151 (100 nM; 72 hours) causes a significant dose- and time-dependent decrease in the proportion of myeloma cells in S/G2 phase.
In Vivo: I-BET151 demonstrates low blood clearance in the rat (~20% liver blood flow) and good oral systemic exposure which resulted in good oral bioavailability. High clearance is observed in the dog (~95% liver blood flow). The systemic exposure in the dog is low, resulting in a poor oral bioavailability of 16%. The high blood clearance in dog correlates well with the high intrinsic clearance observed in dog microsomes and hepatocytes, whereas the low intrinsic clearances seen in rat and mouse (mouse IVC 1.6 mL/min/g; CLb 8 mL/min/kg) correlate with lower in vivo blood clearances in these species. Due to the low systemic exposure observed in the dog, I-BET151 is investigated in the mini-pig as a potential second species for toxicological evaluation where it showed low clearance (~32% liver blood flow) and good bioavailability (65%).
?I-BET151 (30 mg/kg; i.p.; daily for 21 days)-treats mice has four- to five fold smaller myeloma tumors and a significantly reduces rate of tumor size doubling than vehicle-treated mice.
相关产品：Bioactive Compound Library Plus | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Reprogramming Compound Library | Anti-Blood Cancer Compound Library | Heterocyclic Compound Library | (+)-JQ-1 | Curcumin | A-485 | C646 | Revumenib | BRM/BRG1 ATP Inhibitor-1 | BI 2536 | dBET6 | MZ 1 | ARV-825 | Inobrodib | Birabresib | 666-15 | SGC-CBP30 | VTP50469 | ACBI1 | AU-15330 | ARV-771 | dBET1 | dCBP-1 | ABBV-744 | Anacardic Acid | Molibresib | NSC 228155 | KG-501 | A-366 | FHD-286 | Mivebresib | MG 149
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验RUBIS-0027 RUBIS瑞比士 镊子头49J 49J RUBIS-0026 RUBIS瑞比士 SMD镊子572 572 RUBIS-0025 RUBIS瑞比士 镊子7D-13-SA 7D-13-SA RUBIS-0024 RUBIS瑞比士 抛光机DSE-5010 DSE-5010 RUBIS-0023 RUBIS瑞比士 砂轮机TG-151 TG-151 RUBIS-0022 RUBIS瑞比士 镊子OR OR
和14步对提高提取的质量和产率比较重要。 14、加入等体积的PEG-NaCl溶液，轻轻混匀，室温静置30min(大于10min)。 15、配平，4℃下8500rpm离心10min，沉淀用数mL70%乙醇洗。 16、待乙醇挥发干净后，将沉淀溶于1-5mLTE或DDW(双蒸水)中。 溶液配制 一、溶液Ⅰ配制 溶液Ⅰ组成：葡萄糖，EDTA，Tris-HCl。三种物质在溶液Ⅰ中的终浓度分别为：0.05mol/L葡萄糖，0.025mol
Construction of Gene-Targeting Vectors by Recombineering
knockout (cko) targeting vectors using the pSim18 plasmid. This plasmid carries the three phage Red genes (Gam , Bet , and Exo ) under the control of the pL promoter, which is in turn regulated by the temperature-sensitive CI857 repressor
技术资料暂无技术资料 索取技术资料
